Dishman Pharma post standalone Q2 PAT at Rs 13.52cr sans Fx

In an interview to CNBC-TV18 Arpit Vyas, MD of Dishman Pharma gives his views on the company’s second quarter earnings,

Below is the edited transcript of his interview to CNBC-TV18. Q: Can you tell us your net profit and revenue? A: On a standalone basis, this quarter we have done Rs 121 crore. If we don’t consider the forex impact, then the profit after tax (PAT) stands at Rs 13.52 crore. Q: What about consolidated numbers? A: We have done Rs 352 crore and PAT is Rs 42 crore, if we don’t consider forex impact. Q: If you consider forex impact, the reported net profit would be? A: On a consolidated basis, it remains almost the same as we have a few forex gains in Carbogen Amcis, our subsidiary in Switzerland. It is around Rs 42 crore. Q: Could you tell us what the margins were? A: EBITDA level on a consolidated basis is around 27 percent. Q: Can you give us some more details, how the contract research and manufacturing services (CRAMS) and the other businesses did? A: The CRAMS business on a consolidated level was Rs 250 crore. CRAMS and marketable molecules were around Rs 100 crore.